MYRIAD GENETICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
MYRIAD GENETICS, INC. (MYGN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $7.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-07-31
- MYRIAD GENETICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $7.20M, a 32.71% decline year-over-year.
- MYRIAD GENETICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $6.50M, a 31.58% decline year-over-year.
- MYRIAD GENETICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $12.20M, a 1.61% decline year-over-year.
- MYRIAD GENETICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $10.70M, a 26.21% decline year-over-year.
- MYRIAD GENETICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $35.20M, a 29.32% decline from fiscal 2024.
- MYRIAD GENETICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $49.80M, a 22.36% increase from fiscal 2023.
- MYRIAD GENETICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $40.70M, a 6.82% increase from fiscal 2022.
- MYRIAD GENETICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $38.10M, a 4.38% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $7.20M 10-Q · filed 2026-07-31 | $13.70M derived: sum of 2 quarters · filed 2026-07-31 | |||
| 2026-03-31 | $6.50M 10-Q · filed 2026-07-31 | ||||
| 2025-12-31 | $35.20M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $12.20M 10-Q · filed 2025-11-04 | $22.90M derived: sum of 2 quarters · filed 2026-07-31 | $32.40M derived: sum of 3 quarters · filed 2026-07-31 | ||
| 2025-06-30 | $10.70M 10-Q · filed 2026-07-31 | $20.20M derived: sum of 2 quarters · filed 2026-07-31 | |||
| 2025-03-31 | $9.50M 10-Q · filed 2026-07-31 | ||||
| 2024-12-31 | $49.80M 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $12.40M 10-Q · filed 2025-11-04 | $26.90M derived: sum of 2 quarters · filed 2025-11-04 | $38.90M derived: sum of 3 quarters · filed 2025-11-04 | ||
| 2024-06-30 | $14.50M 10-Q · filed 2025-11-04 | $26.50M derived: sum of 2 quarters · filed 2025-11-04 | |||
| 2024-03-31 | $12.00M 10-Q · filed 2025-11-04 | ||||
| 2023-12-31 | $40.70M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $11.60M 10-Q · filed 2024-11-08 | $22.80M derived: sum of 2 quarters · filed 2024-11-08 | $30.30M derived: sum of 3 quarters · filed 2024-11-08 | ||
| 2023-06-30 | $11.20M 10-Q · filed 2024-11-08 | $18.70M derived: sum of 2 quarters · filed 2024-11-08 | |||
| 2023-03-31 | $7.50M 10-Q · filed 2024-11-08 | ||||
| 2022-12-31 | $38.10M 10-K · filed 2025-02-28 | ||||
| 2022-09-30 | $9.40M 10-Q · filed 2023-11-07 | $19.80M derived: sum of 2 quarters · filed 2023-11-07 | $29.90M derived: sum of 3 quarters · filed 2023-11-07 | ||
| 2022-06-30 | $10.40M 10-Q · filed 2023-11-07 | $20.50M derived: sum of 2 quarters · filed 2023-11-07 | |||
| 2022-03-31 | $10.10M 10-Q · filed 2023-11-07 | ||||
| 2021-12-31 | $36.50M 10-K · filed 2024-02-28 | ||||
| 2021-09-30 | $10.00M 10-Q · filed 2022-11-02 | $18.90M derived: sum of 2 quarters · filed 2022-11-02 | $27.90M derived: sum of 3 quarters · filed 2022-11-02 | $34.40M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | $8.90M 10-Q · filed 2022-11-02 | $17.90M derived: sum of 2 quarters · filed 2022-11-02 | $24.40M derived: sum of 3 quarters · filed 2023-03-01 | $32.80M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | $9.00M 10-Q · filed 2022-11-02 | $15.50M derived: sum of 2 quarters · filed 2023-03-01 | $23.90M derived: sum of 3 quarters · filed 2023-03-01 | $25.80M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | $6.50M derived: 10-K 6 month − 10-Q 3 month · filed 2023-03-01 | $14.90M 10-K · filed 2023-03-01 | $16.80M derived: sum of 3 quarters · filed 2023-03-01 | $24.30M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-09-30 | $8.40M 10-Q · filed 2021-11-04 | $10.30M derived: sum of 2 quarters · filed 2021-11-04 | $17.80M derived: sum of 3 quarters · filed 2021-11-04 | $24.80M derived: sum of 4 quarters · filed 2021-11-04 | |
| 2020-06-30 | $1.90M 10-Q · filed 2021-11-04 | $9.40M derived: sum of 2 quarters · filed 2021-11-04 | $16.40M derived: sum of 3 quarters · filed 2021-11-04 | $25.20M 10-K · filed 2023-03-01 | |
| 2020-03-31 | $7.50M 10-Q · filed 2021-11-04 | $14.50M derived: sum of 2 quarters · filed 2021-11-04 | $23.30M derived: sum of 3 quarters · filed 2021-11-04 | ||
| 2019-12-31 | $7.00M 10-Q · filed 2020-05-06 | $15.80M derived: sum of 2 quarters · filed 2020-11-09 | |||
| 2019-09-30 | $8.80M 10-Q · filed 2020-11-09 | ||||
| 2019-06-30 | $33.50M 10-K · filed 2022-02-25 | ||||
| 2019-03-31 | $9.50M 10-Q · filed 2020-05-06 | $17.00M derived: sum of 2 quarters · filed 2020-05-06 | $24.70M derived: sum of 3 quarters · filed 2020-05-06 | ||
| 2018-12-31 | $7.50M 10-Q · filed 2020-05-06 | $15.20M derived: sum of 2 quarters · filed 2020-05-06 | |||
| 2018-09-30 | $7.70M 10-Q · filed 2020-05-06 | ||||
| 2018-06-30 | $27.10M 10-KT · filed 2021-03-16 | ||||
| 2018-03-31 | $6.60M 10-Q · filed 2019-05-08 | $13.50M derived: sum of 2 quarters · filed 2019-05-08 | $19.90M derived: sum of 3 quarters · filed 2019-05-08 | ||
| 2017-12-31 | $6.90M 10-Q · filed 2019-05-08 | $13.30M derived: sum of 2 quarters · filed 2019-05-08 | |||
| 2017-09-30 | $6.40M 10-Q · filed 2019-05-08 | ||||
| 2017-06-30 | $29.90M 10-K · filed 2019-08-13 | ||||
| 2016-06-30 | $31.60M 10-K · filed 2018-08-24 | ||||
| 2015-06-30 | $45.70M 10-K · filed 2017-08-09 | ||||
| 2014-06-30 | $27.10M 10-K · filed 2016-08-10 | $27.07M 10-K · filed 2014-08-13 | |||
| 2013-06-30 | $26.60M 10-K · filed 2015-08-12 | $26.61M 10-K · filed 2013-08-14 | |||
| 2012-06-30 | $26.27M 10-K · filed 2014-08-13 | ||||
| 2011-06-30 | $25.09M 10-K · filed 2013-08-14 | ||||
| 2010-06-30 | $22.78M 10-K · filed 2012-08-15 | ||||
| 2009-06-30 | $25.68M 10-K · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |